The medication can also extend the durability of immunization induced by other drugs that are already being tested to treat the disease.
Scientists at the Cincinnati Children’s Hospital Medical Center in the United States have developed a potential vaccine for the four types of Ebola virus that affect humans. The finding was shared by experts in an article published last Thursday (16) in the Journal of Virology.
According to the researchers, the drug has undergone pre-clinical tests and proved to be effective against the four viruses that cause the disease. The vaccine can also amplify and extend the durability of immunization induced by other drugs that are already being tested for the treatment of the disease.
The world began paying more attention to this disease when an outbreak affected West African countries between 2013 and 2016. Since then, the number of cases has decreased, but some countries continue to be seriously affected by it, such as the Democratic Republic of the Congo.
According to the World Health Organization, since the outbreak in the country began in August 2018, almost 3,500 people have died. Médecins Sans Frontières (MSF) report that in 2020, the number of registered cases per week has decreased dramatically.
Local authorities were expected to declare the outbreak to end on Monday (13), but the appearance of an Ebola case on April 10 canceled the government’s plans. “The outbreak is not yet over and there is a continued need for vigilance,” wrote the MSF on its website.
In previous studies, scientists around the world focused on a glycoprotein from the Zaire Ebola virus, which can be transformed into a modified live viral vector. When these molecules are administered to a patient, they induce immunological responses against the Ebola glycoprotein, protecting the person against the microorganism.
The new vaccine takes another approach, according to the study. The researchers designed a bivalent particle similar to the spherical type of the Ebola virus. These two genetically diverse glycoproteins are inserted into a round nucleus and then incorporated into the drug.
According to scientists, this makes the vaccine work by stimulating immune responses against the different genetic codes of Ebola. The result is the production of antibodies to the four varieties of the disease.